



2Q21 - COMMITMENTS AND DELIVERIES



MIGRATION TO B3'S NOVO MERCADO



- Conversion of Preferential Shares into Common Shares completed;
- Migration should occur within in the month of August



GROWTH



- Sales growth (+28.9%);
- Market Share gains in all states of the Southern Region;
- Average sale per store growth higher than presented by the Market;
- Significant increase in the Panvel's NPS (focus in the customer).



HEALTH HUB



- Record participation in retail sales;
- Increase in the number of Clinic Rooms;
- Increase in the number of Vaccination Rooms;
- Increase in the number of Covid-19 Quick Testing rooms.





Greater market share, growing compared to 1Q21.



INVESTIMENTS



- Stores expansion;
- Logistic (new DC in São José dos Pinhais/PR).



HIGHLIGHTS



Gross Retail Revenue

R\$ 766.8 M

+28.9% vs 2Q20



Gross Margin Retail

30.2%

+1.4 P.P. vs 2Q20

Net Income



R\$ 24.2 M

Net Margin: 2.9% +242.1% vs 2Q20



Digital Share



16.1%

of Retail Sales

Adjusted EBITDA



R\$ 39.9 M

Margem: 4.8% +107.1% vs 2Q20

NPS



80

+ 4 points vs 1Q21









CONSISTENT GROWTH OVER THE YEARS





Evolution – Average Sale per Store











2Q21: RETAIL REVENUE GROWS 28,9% VS 2Q20












2Q21: SSS GROWS 19.9% AND MSS 16.7%. SALES PER STORE GROWS ABOVE THE MARKET











EXPANSION ACCELERATES IN 2Q21 WITH 20 STORE OPENINGS













PANVEL KEEPS GAINING MARKET SHARE IN ALL STATES OF SOUTHERN REGION



Digital Market Share – 2Q21











PANVEL HAS BIGGEST DIGITAL CHANNELS PENETRATION AND FASTEST DELIVERY IN BRAZIL

(Digital - % Share in Retail)



% Sales e-comerce over Total Sales (2Q21)



- Fastest delivery in pharma retail
- Best NPS of segment
- Personalized Journey for customer
- Product and service portfolio

31% OF DELIVERIES IN 1H











Deliveries 2Q21 595.300 (+4.7% *vs* 2Q20)

Ship from DC

2 DC's (RS and PR)



Service Level

97%








PANVEL OFFERS THE BEST EXPERIENCE FOR THE COSTUMER

























PANVEL CLINIC BREAK RECORD OF PARTICIPATIONS IN RETAIL SALES



Structure

Coverage: all states in which we operate

Stores Panvel Clinic: 286 (+275% *vs* 2Q20)

Vaccination Rooms: 60 (+46.3% *vs* 2Q20)

Covid Testing Rooms: 251 (2Q21)

Todas novas lojas abrem com Clinic



Leader in vaccination in Southern Region: 39.9% of *Market Share*

Source: IQVIA



Leader in quick tests in Southern Region: 22.1% de *Market Share*

Source: IQVIA



5.4% of Retail Sales



First chain to close partnership with public authorities for Covid-19 vaccination (+60k vaccines applied)



Results 2Q21


Available services: +100 available services

Vaccines Applied: +120k (+341.4% *vs* 2Q20)

Covid-19 Quick Tests: +250k (23.4% *vs* 1Q21)

Other Services: +77k (+124.8% *vs* 2Q20)

Share in Retail Sales











PANVEL PRODUCTS: CONSISTENCY WITH QUALITY AND PROFITABILITY



7.4% of Retail Sales in 2Q21

19.4%
of HB's Sales in
2021



grupcalimed








GROSS MARGIN RETAIL REMAINS ONE OF THE SOUNDEST OF MARKET, MAINTAINING HIGH LEVEL

Gross Margin - Retail











1T21: DESPESAS CONTROLADAS COM PRESSÃO NO CURTO PRAZO EM FUNÇÃO DE INVESTIMENTOS E CRESCIMENTO ACELERADO


Selling Expenses



General and Administrative Expenses



Employees per Store












ADJUSTED EBITDA GROWS 107.1% IN 2Q21, AN EVOLUTION OF 1.9 P.P.


Adjusted EBITDA - Group





EBITDA - Retail













2Q21 NET INCOME GROWS 242,1% IN 2Q21, AN INCREASE OF 1.8 P.P.

Adjusted Net Income












CASH CYCLE STARTS NORMALIZATION PROCESS WITH REDUCTION OF INVENTORIES



- Pre-price readjustment purchases
- DC Passo Fundo/RS transition









STRATEGIC PILLARS OF SUSTAINABLE GROWTH AND PROFITABILITY















IT AND INFRASTRUCTURE



PEOPLE AND CULTURE










EXPANSION: PHYSICAL STORE AT THE CENTER OF THE STRATEGY



48%

Performance of New Stores



New stores reach 80% of the network's average sales in less than 12 months

Points prospected









ROADMAP DIGITAL



- Website Redesign
- Improvements in UX (User Experience)
- **★** Improvements in Search tool
- Long Tail

Product Marketplace

2022



WELL-BEING



HEALTH



NUTRITION












PANVEL CLINIC: A HUB OF NEWS















→ Use of Chatbot

Panvel Special Medicines

A solution dedicated to all beneficiaries of health insurance Operators, whose use medicines to chronical and oncological diseases.

Patients are monitored by a team of pharmacists that help to improve quality of life of the patients and to control loss ratio of Health Insurance Operators








PROGRAMA BEM PANVEL












7% Omni Costumers

Average Ticket 3x Bigger

12 identified purchase behaviors Ex.: Chronical and Continuous

Digital Coupon Wallet













Todos bein

Cuidar de todos é cuidar de cada um.



<u>Click here</u> to access our Platform



<u>Click here</u> to access our Manifest





INCLUSION AND DIVERSITY



WOMEN'S LEADERSHIP Administrative Council

1ª Recommendation

Direction Office30.0%

Management
Office
72.5%

% of employees 71,9%



BLACK/BROWN LEADERSHIP

19%



To promote inclusion of diversity in our group of employees and reinforce their role in Society, the Grupo Dimed created, in 2012, the **Programa Juntos**

SOCIAL AND ENVIRONMENTAL RESPONSIBILITY













5 Power Plant

4º Largest

Carport in Brazil

Renewable
Energy
40% of Stores





CORPORATE GOVERNANCE



B3'S NOVO MERCADO MIGRATION





- Election of 2° Independent Member of Board of Directors;
- Bylaw's actualization, as required by B3.

MIGRATION WILL OCCUR IN

AUGUST/21







grupodimed.com.br









Investor Relations

Antônio Carlos Tocchetto Napp CFO and IRO

> **Ismael Rohrig** IR Analyst

Te.: (51) 3481.9999 / 3481.9588 relinvest@dimed.com.br grupodimed.com.br/ri

